» Articles » PMID: 2848196

Oncogenic Potential of Bcl-2 Demonstrated by Gene Transfer

Overview
Journal Nature
Specialty Science
Date 1988 Nov 17
PMID 2848196
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Follicular lymphoma is the most common human B-cell malignancy in the United States and Western Europe. Most of the tumours contain t(14;18) chromosome translocations involving the human bcl-2 gene. Translocation of bcl-2 sequences from chromosome 18 into the transcriptionally active immunoglobulin locus at chromosome band 14q32 in B cells deregulates bcl-2 gene expression, resulting in the accumulation of high levels of bcl-2 messenger. Human bcl-2 transcripts generate two proteins, p26 bcl-2-alpha and p22 bcl-2-beta, by virtue of alternative splice-site selection. Both proteins have in common their first 196 NH2-terminal amino acids but share little similarity with other sequences in a data bank. Although the biological and biochemical functions of bcl-2 are unknown, recent subcellular localization studies indicate that p26 bcl-2-alpha associates with cellular membranes, consistent with a stretch of hydrophobic amino acids in its carboxy terminus. The bcl-2 gene may represent a novel oncogene having no known retroviral counterpart. Here we demonstrate the oncogenic potential of bcl-2 through a gene transfer approach.

Citing Articles

NAALADL2-AS2 functions as a competing endogenous RNA to regulate apoptosis and drug resistance in DLBCL.

Xu X, Liu J, Fang C, Deng X, Zhu D, Jiang J Cancer Biol Ther. 2024; 25(1):2432690.

PMID: 39575888 PMC: 11587827. DOI: 10.1080/15384047.2024.2432690.


Orexins in apoptosis: a dual regulatory role.

Cavalu S, Saber S, Hamad R, Abdel-Reheim M, Elmorsy E, Youssef M Front Cell Neurosci. 2024; 18:1336145.

PMID: 38699177 PMC: 11064656. DOI: 10.3389/fncel.2024.1336145.


The immune microenvironment of cancer of the uterine cervix.

Mastrogeorgiou M, Chatzikalil E, Theocharis S, Papoudou-Bai A, Peoch M, Mobarki M Histol Histopathol. 2024; 39(10):1245-1271.

PMID: 38483012 DOI: 10.14670/HH-18-727.


Applications of synthetic biology in medical and pharmaceutical fields.

Yan X, Liu X, Zhao C, Chen G Signal Transduct Target Ther. 2023; 8(1):199.

PMID: 37169742 PMC: 10173249. DOI: 10.1038/s41392-023-01440-5.


Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma.

Ma Z, Xie T, Sun J, Yu J, Huang S, Zhou Q BMC Cancer. 2023; 23(1):404.

PMID: 37142983 PMC: 10161465. DOI: 10.1186/s12885-023-10810-9.